1887
  1. Home
  2. Eurosurveillance
  3. Volume 31, Issue 9, 05/Mar/2026
  4. Article
Surveillance Open Access
Like 0
Download

2025 theme: Vaccines

Abstract

BACKGROUND

Global resurgence of measles highlights the need for countries to identify and address immunity gaps. This is challenging given antibody waning and, in Ireland, the absence of robust national vaccine coverage data, population changes due to migration and outdated population-level seroprevalence data from the last national serosurvey (2003).

AIM

We aimed to determine the seroprevalence of measles IgG in children aged 3–17 years in Ireland.

METHODS

Convenience sampling of anonymised residual serum samples from four hospital laboratories across four of six health regions was conducted between 1 February and 19 June 2024. Samples were tested for measles IgG antibodies using a commercial chemiluminescence immunoassay. Seropositivity was adjusted for test sensitivity and specificity and was calculated by sex, age and location.

RESULTS

In total 2,509 of 2,924 samples were seropositive and 415 were seronegative indicating measles IgG seroprevalence of 90.3% (95% confidence interval (CI): 89.2–91.4), with no significant difference by sex. Children aged 3–5 years (94.9%; 95% CI: 92.4–96.6) and 6–9 years (94.2%; 95% CI: 91.7–95.9) had significantly higher seropositivity when compared with children aged 10–13 years (89.1%; 95% CI: 86.6–91.3) and 14–17 years (87.6%; 95% CI: 85.5–89.4).

CONCLUSION

Our findings suggest close to adequate protection against measles among children 3–9 years but suboptimal (< 95%) protection among children aged 10–17 years. This immunity gap is not reflected in measles vaccine coverage data, highlighting the utility of seroprevalence data to enhance knowledge of clinical protection at population level and to inform vaccination strategies.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2026.31.9.2500313
2026-03-05
2026-04-19
/content/10.2807/1560-7917.ES.2026.31.9.2500313
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/31/9/eurosurv-31-9-3.html?itemId=/content/10.2807/1560-7917.ES.2026.31.9.2500313&mimeType=html&fmt=ahah

References

  1. Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. JAMA. 1992;267(9):1237-41.  https://doi.org/10.1001/jama.1992.03480090085032  PMID: 1538561 
  2. Khalil A, Samara A, Campbell C, Ladhani SN. Pregnant women and measles: we need to be vigilant during outbreaks. EClinicalMedicine. 2024;72:102594.  https://doi.org/10.1016/j.eclinm.2024.102594  PMID: 38666235 
  3. World Health Organization (WHO). Measles Factsheet 2024. Geneva: WHO. [Accessed: 23 Apr 2025]. Available from: https://www.who.int/news-room/fact-sheets/detail/measles#:~:text=Measles%20is%20a%20highly%20contagious,being%20between%202000%20and%202022
  4. World Health Organization (WHO). Measles: fighting a global resurgence. Geneva: WHO. [Accessed: 20 Apr 2025]. Available from: https://www.who.int/news-room/feature-stories/detail/measles-fighting-a-global-resurgence
  5. World Health Organization Regional Office for Europe (WHO/Europe). Measles and rubella elimination country profile Ireland. Copenhagen: WHO/Europe; 2020. Available from: https://iris.who.int/bitstream/handle/10665/337779/WHO-EURO-2020-1421-41171-55983-eng.pdf?sequence=2&isAllowed=y
  6. World Health Organization Regional Office for Europe (WHO/Europe). Eliminating measles and rubella in the WHO European Region. Copenhagen: WHO/Europe; 2024. Available from: https://iris.who.int/bitstream/handle/10665/375923/9789289060783-eng.pdf?sequence=1
  7. UK Health Security Agency. Risk assessment for measles resurgence in the UK. London: UK Health Security Agency. [Accessed: 20 Apr 2025]. Available from: https://www.gov.uk/government/publications/measles-risk-assessment-for-resurgence-in-the-uk
  8. Minta AA, Ferrari M, Antoni S, Lambert B, Sayi TS, Hsu CH, et al. Progress Toward Measles Elimination - Worldwide, 2000-2023. MMWR Morb Mortal Wkly Rep. 2024;73(45):1036-42.  https://doi.org/10.15585/mmwr.mm7345a4  PMID: 39541251 
  9. UK Health Security Agency. Measles epidemiology 2023 to 2025. London: UK Health Security Agency. [Accessed: 20 Apr 2025]. Available from: https://www.gov.uk/government/publications/measles-epidemiology-2023
  10. European Centre for Disease Prevention and Control (ECDC). Threat assessment brief. Measles on the rise in the EU/EEA: considerations for public health response. Stockholm: ECDC; 2024. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/measles-eu-threat-assessment-brief-february-2024.pdf
  11. European Centre for Disease Prevention and Control (ECDC). Measles - Annual Epidemiological Report for 2024. Stockholm: ECDC; 2025. Available from: https://www.ecdc.europa.eu/en/publications-data/measles-annual-epidemiological-report-2024
  12. Health Service Executive (HSE). Previous Vaccine Schedules. Dublin: HSE. [Accessed: 12 Apr 2025]. Available from: https://www.hse.ie/eng/health/immunisation/whoweare/vacchistory.html
  13. Health Service Executive (HSE). Current Immunisation Schedule 2024. Dublin: HSE. [Accessed: 10 Apr 2025]. Available from: https://www2.hse.ie/babies-children/vaccines-your-child/.
  14. Health Protection Surveillance Centre (HPSC). Immunisation uptake statistics at 12 and 24 months of age quarterly reports - 2024. Dublin: HPSC. [Accessed: 10 Apr 2025]. Available from: https://www.hpsc.ie/a-z/vaccinepreventable/vaccination/immunisationuptakestatistics/immunisationuptakestatisticsat12and24monthsofage/quarterlyreports/2024/Immunisation%20uptake%20in%20Ireland%20at%2012%20and%2024%20months-%20Q1%202024%20v1.0.xlsx
  15. Central Statistics Office. Census of Population 2022 - Summary Results. Migration and Diversity. Cork: Central Statistics Office. [Accessed: 10 Apr 2025]. Available from: https://www.cso.ie/en/releasesandpublications/ep/p-cpsr/censusofpopulation2022-summaryresults/migrationanddiversity/
  16. Andrews N, Tischer A, Siedler A, Pebody RG, Barbara C, Cotter S, et al. Towards elimination: measles susceptibility in Australia and 17 European countries. Bull World Health Organ. 2008;86(3):197-204.  https://doi.org/10.2471/BLT.07.041129  PMID: 18368206 
  17. Health Protection Surveillance Centre (HPSC). Prevalence of measles IgG antibodies in adults aged 18-34 years in Ireland, 2022. Dublin: HPSC; 2023. Available from: https://www.hpsc.ie/a-z/nationalserosurveillanceprogramme/measlesserosurveillance/surveillancereports/NSP_adult_measles_report_20240219.pdf
  18. Medical Laboratory Scientists Association (MLSA). Medical Scientist Recruitment and Retention Submission to the Department of Health and Health Service Executive September 2020. Dublin: MLSA; 2020. Available from: https://mlsa.ie/sites/default/files/files/MLSA%20Recruitment%20and%20Retention%20Submission%20to%20HSE-DOH%20Sept%2020.pdf
  19. Health Service Executive (HSE) National Health Intelligence Unit. Population Profile. Atlas Finder report. Dublin: HSE. [Accessed: 28 Jun 2024]. Available from: https://finder.healthatlasireland.ie/
  20. United Nations (UN). Convention on the Rights of the Child. New York: UN; 1989. Available from: https://treaties.un.org/doc/Treaties/1990/09/19900902%2003-14%20AM/Ch_IV_11p.pdf
  21. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020. Available from: http://www.Rproject.org/
  22. National Institute for Biological Standards and Control (NIBSC). World Health Organization and Medicines and Healthcare products Regulatory Agency. World Health Organization International Standard. 3rd International Standard for Anti-Measles. Potters Bar: NIBSC; 2008. Available from: https://nibsc.org/documents/ifu/97-648.pdf
  23. Health Protection Surveillance Centre (HPSC). Annual Epidemiological Report; Measles in Ireland, 2018. Dublin: HPSC; 2019. Available from: https://www.hpsc.ie/a-z/vaccinepreventable/measles/surveillancereports/annualreportsonmeaslesinireland/Measles%20-%20Annual%20Summary%202018.pdf
  24. Health Protection Surveillance Centre (HPSC). Immunisation uptake statistics at 12 and 24 months of age - data up to Quarter 1 2025. Dublin: HPSC. [Accessed: 10 Mar 2025]. Available from: https://www.hpsc.ie/a-z/vaccinepreventable/vaccination/immunisationuptakestatistics/immunisationuptakestatisticsat12and24monthsofage/
  25. Rogan WJ, Gladen B. Estimating prevalence from the results of a screening test. Am J Epidemiol. 1978;107(1):71-6.  https://doi.org/10.1093/oxfordjournals.aje.a112510  PMID: 623091 
  26. Health Protection Surveillance Centre (HPSC). Vaccine uptake in junior infants and children aged 4-5 years in Ireland, 2022/2023. Dublin: HPSC; 2024. Available from: https://www.hpsc.ie/a-z/vaccinepreventable/vaccination/immunisationuptakestatistics/immunisationuptakestatisticsforjuniorinfants/2022-2023%20DTaP-IPV%20%20MMR%20Vaccine%20Uptake%20in%20Junior%20infantschildren%20aged%204-5%20years%20Ireland_Final.%20V2.0.pdf
  27. World Health Organization (WHO). Targeted and selective strategies in measles and rubella vaccination campaigns. Interim guidance. Geneva: WHO; 2024. Available from: https://iris.who.int/server/api/core/bitstreams/1a6c0ef6-e711-4006-9fb4-ba1caba604c9/content
  28. Anichini G, Gandolfo C, Fabrizi S, Miceli GB, Terrosi C, Gori Savellini G, et al. Seroprevalence to Measles Virus after Vaccination or Natural Infection in an Adult Population, in Italy. Vaccines (Basel). 2020;8(1):66.  https://doi.org/10.3390/vaccines8010066  PMID: 32028593 
  29. Friedrich N, Poethko-Müller C, Kuhnert R, Matysiak-Klose D, Koch J, Wichmann O, et al. Seroprevalence of Measles-, Mumps-, and Rubella-specific antibodies in the German adult population - cross-sectional analysis of the German Health Interview and Examination Survey for Adults (DEGS1). Lancet Reg Health Eur. 2021;7:100128.  https://doi.org/10.1016/j.lanepe.2021.100128  PMID: 34557838 
  30. Poethko-Müller C, Mankertz A. Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity. PLoS One. 2012;7(8):e42867.  https://doi.org/10.1371/journal.pone.0042867  PMID: 22880124 
  31. Schenk J, Abrams S, Litzroth A, Cornelissen L, Grammens T, Theeten H, et al. Identifying immunity gaps for measles using Belgian serial serology data. Vaccine. 2022;40(26):3676-83.  https://doi.org/10.1016/j.vaccine.2022.05.009  PMID: 35589453 
  32. Hu S, Logan N, Coleman S, Evans C, Willett BJ, Hosie MJ. Correlating IgG Levels with Neutralising Antibody Levels to Indicate Clinical Protection in Healthcare Workers at Risk during a Measles Outbreak. Viruses. 2022;14(8):1716.  https://doi.org/10.3390/v14081716  PMID: 36016338 
Cross-sectional seroprevalence study of measles antibodies among children to identify gaps in population immunity, Ireland, 2024
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Melissa+Brady&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Brady Melissa</a>, <a href="/search?value1=Lieke+Brouwer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Brouwer Lieke</a>, <a href="/search?value1=Katie+O%E2%80%99+Brien&option1=author&noRedirect=true" class="nonDisambigAuthorLink">O’ Brien Katie</a>, <a href="/search?value1=Michael+Carton&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Carton Michael</a>, <a href="/search?value1=Laura+Whitton&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Whitton Laura</a>, <a href="/search?value1=Claire+Dillon&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Dillon Claire</a>, <a href="/search?value1=Jane+Finucane&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Finucane Jane</a>, <a href="/search?value1=Fiona+Culkin&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Culkin Fiona</a>, <a href="/search?value1=Ellen+Perry&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Perry Ellen</a>, <a href="/search?value1=Elaine+Brabazon&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Brabazon Elaine</a>, <a href="/search?value1=Sarah+Gee&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Gee Sarah</a>, <a href="/search?value1=Kate+Browne&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Browne Kate</a>, <a href="/search?value1=Deirdre+Burke&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Burke Deirdre</a>, <a href="/search?value1=Cillian+De+Gascun&option1=author&noRedirect=true" class="nonDisambigAuthorLink">De Gascun Cillian</a>, <a href="/search?value1=Ann+Leonard&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Leonard Ann</a>, <a href="/search?value1=Robert+Cunney&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Cunney Robert</a>, <a href="/search?value1=Lois+O%E2%80%99+Connor&option1=author&noRedirect=true" class="nonDisambigAuthorLink">O’ Connor Lois</a></span>. Cross-sectional seroprevalence study of measles antibodies among children to identify gaps in population immunity, Ireland, 2024. <a href="/content/ecdc">Euro Surveill.</a> 2026;31(9):pii=2500313. <a href="https://doi.org/10.2807/1560-7917.ES.2026.31.9.2500313" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2026.31.9.2500313</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 09 May 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 14 Dec 2025 </span> </p>
/content/10.2807/1560-7917.ES.2026.31.9.2500313
/content/10.2807/1560-7917.ES.2026.31.9.2500313
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error